Vancouver, WA (PRWEB) September 28, 2011
Oasis Diagnostics Corporation has licensed technology for the non-invasive diagnosis of Alzheimer's disease and Parkinson's disease from Drs Balwant Rai and Jasdeep Kaur. Using a series of proprietary biomarkers Oasis will develop a rapid saliva test for these debilitating diseases in its patented VerOFy point-of-care testing platform device.
Two collaborators will use a point of care testing tool and up to eight specific proprietary biomarkers found in saliva for diagnosis, prognosis and monitoring of Alzheimer’s and Parkinson’s diseases.
Founded in 2007 by Dr. Paul D. Slowey, Oasis Diagnostics® develops, manufactures and distributes saliva diagnostic and standardized collection tools. The goal is to meet a worldwide and increasing demand for fast, accurate, convenient and painless saliva tests.
Oasis recently executed an exclusive, global license for the technology from the inventors (Drs. Balwant Rai and Jasdeep Kaur, “RAIKAUR”) who have demonstrated that 50 different biomarkers are contributory to Alzheimer’s disease but as few as three can lead to accurate diagnosis using the Oasis VerOFy® point of care testing tool.
The VerOFy® Rapid Test Platform is an enabling technology for rapid point of care diagnosis using saliva specimens. In this case, it will be able to accomodate a test for Alzheimer’s disease diagnosis by detecting specific concentrations of each of eight biomarkers that collectively provide a high degree of accuracy (sensitivity and specificity) for Alzheimer’s disease. The VerOFy® technology was originally developed for roadside drugs of abuse testing, but may be applied to a multitude of diseases, disease states or biomarkers for use in any setting where immediate results are required.
Current methods for diagnosis of Alzheimer’s disease involve a brain biopsy (only available upon death), less than definitive imaging techniques, biomarkers in cerebrospinal fluid (a difficult sample to obtain) and multi-modal techniques involving the combination of neural imaging and fluid biomarkers.
Diagnosis of Parkinson’s disease is also very difficult to attain due to its dependence on clinical examination and physician judgment, which can create the potential for bias. “Currently, there is no diagnostic test that can confirm Parkinson's disease. Laboratory testing of the blood of patients with the symptoms typical of Parkinson's only rarely uncovers any abnormality,” according to the University of Maryland Parkinson’s Disease Center in Baltimore.
“Three salivary biomarkers, said Dr Rai, may be sufficient to diagnose Parkinson’s disease at an early stage. These biomarkers have very high specificity and sensitivity.”
“RAIKAUR chose Oasis as its partner for the (testing) technology based on its reputation as one of the leading oral fluid diagnostics companies in the world,” said Dr. Rai. The Company’s experience in the development and commercialization of innovative salivary diagnostic tools is unique.”
Added Dr. Slowey: “We believe the VerOFy® Alzheimer’s test will revolutionize the way the disease is diagnosed by providing a tool for clinics, physicians’ offices and, eventually, over the counter. It will facilitate earlier detection, earlier enrollment into available treatment protocols and may be used as a tool to monitor the effectiveness of new therapies entering the market. Undoubtedly, VerOFy® will be used for ongoing research into this debilitating disease.”
According to a paper in the acclaimed scientific journal “Nature” “Alzheimer's disease affects millions of people around the world. Currently, there are no treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's disease is characterized by protein misfolding in the brain. This process and the associated brain damage begin years before the substantial neurodegeneration that accompanies dementia. Studies using new neuroimaging techniques and fluid biomarkers suggest that Alzheimer's disease pathology can be detected preclinically. These advances should allow the design of new clinical trials and early mechanism-based therapeutic intervention.” Nature 461, 916-922 (15 October 2009)
About Oasis Diagnostics® Corporation
Oasis Diagnostics® is a Vancouver, WA based company focused on the design, development and commercialization of salivary diagnostic tools with applications at the point-of-care, in the laboratory and for molecular diagnostic testing. The Company has developed a series of oral technologies that are useful in areas such as general wellness, global health, drugs of abuse, infectious diseases, DNA and RNA collection, nucleic acid testing and protein characterization. The Oasis products are protected by a series of US and international patents [visit http://www.4saliva.com for further details].
About Dr. Balwant Rai
Assoc. Professor (Dr) Balwant Rai is the founder of Aeronautic Dentistry and has written the curriculum and guidelines for the implementation of this new discipline. He is Program Director and Associate Professor of Aeronautic Dentistry at KSU in the USA. He is also the President and Founder of the JBR Institute of Health Education Research and Technology. Dr Rai has more than 100 published articles in international and national journals, has written seven books, and is Editor-in-Chief of four international journals and Executive Deputy Editor of Aeronautic Dentistry. He is also founder of the BR formula and BR regression equation used in forensic technology. His current work involves the effect of micro-gravity on the oral cavity, human physiology and psychology and non-invasive biomarkers, including the elaboration of technologies to prevent the adverse effects of microgravity on the human physiology. His biography has been published in Who’s Who in Health and Medicine and Who’s Who in the World, USA. He is invited Editor of Mars Quarterly. He is an invited reviewer to NRF, South Africa, reviewer of more than 10 different journals, and has seven pending patents. He is an invited reviewer of many national and international indexed journals. He was selected as part of Crew 78 on the Mars Desert Research Station [MDRS] as Health and Safety Officer and appointed as Commander for 100 B crew, on MDRS. He is principal investigator cum researcher on a project entitled “simulated micro-gravity and human factors including oral cavity: non invasive technology”. Dr Rai is working with different space related research projects and has been an invited judge for different space related programs. He has a strong belief in leaving a mark on space programs using non-invasive diagnostic technologies.
About Dr. Jasdeep Kaur
Dr. Kaur has recently been awarded the Henry Thortson Award in the U.S. for her achievements and has presented her research at the Greater New York Dental Meeting and the Chicago Midwinter Meeting in February 2009. She has also been invited to present her work at various European dental school locations. Kaur is Editor in Chief of the Journal of Aeronautic Dentistry and Executive Editor of the Journal of Forensic Odontology and the Journal of Dental Education. She has more than fifty (50) published articles in international and national journals and published three books. Dr. Kaur has six patents (pending) based on her research studies. She is currently working on the effect of microgravity on the human body. She was selected as part of Crew 100B, on the Mars Desert Research Station [MDRS] as Health and Safety Officer.
Forward Thinking Statements
Portions of this press release may contain forward-looking statements regarding future events and undertakings of OASIS and / or RAIKAUR. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from any future performance suggested in such statements. OASIS and RAIKAUR do not undertake any obligation to publicly update any forward-looking statements as a result of new information, future events or otherwise. OASIS and RAIKAUR urge interested parties to consider all of these risks, uncertainties and other factors carefully in evaluating these forward-looking statements made in this release and not to place undue reliance on such statements. As a result of these and other matters, including changes in facts, assumptions not being realized or other circumstances, our actual results may differ materially from those discussed in the forward-looking statements. The forward-looking statements included in this release are made only as of the date of this release, and we undertake no obligation to update it to reflect subsequent events or circumstances.